Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Krebs von den Lungen-6 as biomarker of the new progressive fibrotic phenotype of interstitial lung disease.

Tissue & cell - 1 Oct 2024

d'Alessandro Miriana, Conticini Edoardo, Bergantini Laura, Mazzei Maria Antonietta, Bellisai Francesca, Selvi Enrico, Cameli Paolo, Frediani Bruno, Bargagli Elena

Abstract excerpt

BACKGROUND: Novel progressive fibrotic phenotype has recently been proposed characterized by progressive and inexorable worsening of the disease. Krebs von den Lungen-6 (KL-6) has been proposed as fibrotic-ILD biomarker. We aimed to assess the role of KL-6 in fibrotic-ILD and the progressive phenotype in accordance with serial serum KL-6. METHODS: 107 patients were enrolled in the study (median age,IQR,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to Fibrosis

Share to Lung Diseases, Interstitial

Share to Mucin-1

Share to Phenotype

Source

Identifiers

PMID: 39137538
DOI: 10.1016/j.tice.2024.102516

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Krebs von den Lungen-6 as biomarker of the new progressive fibrotic phenotype of interstitial lung disease.PMID 39137538Read ↗

Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype.Semantic proximity Read ↗

Progressive fibrosing interstitial lung disease: prevalence and clinical outcome.Semantic proximity Read ↗

Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases.Semantic proximity Read ↗

Update on the diagnosis and classification of ILD.Semantic proximity Read ↗

An IPF-like disease course in disorders other than IPF: how can this be anticipated, recognized, and managed?Semantic proximity Read ↗

When things go wrong: exploring possible mechanisms driving the progressive fibrosis phenotype in interstitial lung diseases.Semantic proximity Read ↗

Prevalence and prognosis of chronic fibrosing interstitial lung diseases with a progressive phenotype.Semantic proximity Read ↗

Compare three diagnostic criteria of progressive pulmonary fibrosisSemantic proximity Read ↗

Periostin: A Biomarker Useful in Treating Patients with Progressive Fibrosing Interstitial Lung DiseasesSemantic proximity Read ↗

Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.Semantic proximity Read ↗

Biopsy in interstitial lung disease: specific diagnosis and the identification of the progressive fibrotic phenotype.Semantic proximity Read ↗

Progressive fibrotic interstitial lung disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.